International consensus on methotrexate dosing for patients with atopic dermatitis: An eDelphi study

International consensus on methotrexate dosing for patients with atopic dermatitis: An eDelphi study

Despite the widespread off-label use of methotrexate (MTX) for the treatment of atopic dermatitis (AD), there is limited high-quality evidence on dosing regimens and existing guidelines do not provide clear recommendations regarding dosing strategies. The aim of this study was to achieve internation...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the European Academy of Dermatology and Venereology 2024-08
Hauptverfasser: Caron, Anouk G M, van Huizen, Astrid M, Musters, Annelie A H, Gerbens, Louise A A, Middelkamp Hup, Maritza A, Flohr, Carsten, Irvine, Alan D, Vestergaard, Christian, Peris, Ketty, Brandling-Bennett, Heather A, Drucker, Aaron M, Spuls, Phyllis I
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title Journal of the European Academy of Dermatology and Venereology
container_volume
creator Caron, Anouk G M
van Huizen, Astrid M
Musters, Annelie A H
Gerbens, Louise A A
Middelkamp Hup, Maritza A
Flohr, Carsten
Irvine, Alan D
Vestergaard, Christian
Peris, Ketty
Brandling-Bennett, Heather A
Drucker, Aaron M
Spuls, Phyllis I
description Despite the widespread off-label use of methotrexate (MTX) for the treatment of atopic dermatitis (AD), there is limited high-quality evidence on dosing regimens and existing guidelines do not provide clear recommendations regarding dosing strategies. The aim of this study was to achieve international consensus among AD experts to standardize the dosing regimen for MTX treatment in adults and children with AD. An electronic Delphi (eDelphi) study was conducted from October 2021 to September 2022. Recruitment was conducted through dermatology societies and AD interest groups. Participation was open to dermatologists and dermatology residents experienced in treating AD patients with MTX. The study consisted of three online rounds. The first round was informed by a systematic review of relevant literature, and subsequent rounds were adjusted based on the results of the previous round. Participants voted on 19 proposals using a 9-point scale (1-3 disagree, 4-6 neither agree nor disagree, 7-9 agree). Consensus was achieved when at least 70% of participants agreed, and less than 15% disagreed. Proposals that did not reach consensus in the first three rounds were discussed in a consensus meeting, where consensus was defined as less than 30% disagreement. In total, 152 participants completed Round 1, 104 (68%) completed all survey rounds, and 43 (28%) joined the consensus meeting. Consensus was achieved on 7 proposals in Round 1, 4 in Round 2 and 6 in Round 3. The final 2 proposals reached consensus during the consensus meeting. Consensus topics include test dose, start dose, maximum dose, administration route, dosing schedule, management of stopping treatment, treatment duration and folic acid supplementation. This eDelphi study achieved consensus on 19 proposals related to MTX dosing for adults and children with AD. These results aim to guide prescribing decisions and encourage a standardized global approach to MTX use in AD.
doi_str_mv 10.1111/jdv.20271
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3086956970</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3086956970</sourcerecordid><originalsourceid>FETCH-LOGICAL-c210t-cfbd5e078a314eb9c2f96cf161ed446d1924565b3f9859b34ebd56e80da8ab233</originalsourceid><addsrcrecordid>eNo90D1PwzAQgGELgWgpDPwB5BGGFDtOnJitKl-VKrHAHDn2hbpK7GA7QP89AQq3nHR6dMOL0DklczrO9Va_z1OSFvQATWnGy4SRkh2iKREpT4TIxQSdhLAlhFCal8dowgQpC874FOmVjeCtjMZZ2WLlbAAbhoCdxR3EjYsePmUErF0w9hU3zuN-1GBjwB8mbrCMrjcKa_DdeI8m3OCFxXALbb8xOMRB707RUSPbAGf7PUMv93fPy8dk_fSwWi7WiUopiYlqap0DKUrJaAa1UGkjuGoop6CzjGsq0iznec0aUeaiZqPROYeSaFnKOmVshi5___bevQ0QYtWZoKBtpQU3hGrMwkXORUFGevVLlXcheGiq3ptO-l1FSfUdtRqjVj9RR3uxfzvUHeh_-VeRfQGroHQ_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3086956970</pqid></control><display><type>article</type><title>International consensus on methotrexate dosing for patients with atopic dermatitis: An eDelphi study</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Caron, Anouk G M ; van Huizen, Astrid M ; Musters, Annelie A H ; Gerbens, Louise A A ; Middelkamp Hup, Maritza A ; Flohr, Carsten ; Irvine, Alan D ; Vestergaard, Christian ; Peris, Ketty ; Brandling-Bennett, Heather A ; Drucker, Aaron M ; Spuls, Phyllis I</creator><creatorcontrib>Caron, Anouk G M ; van Huizen, Astrid M ; Musters, Annelie A H ; Gerbens, Louise A A ; Middelkamp Hup, Maritza A ; Flohr, Carsten ; Irvine, Alan D ; Vestergaard, Christian ; Peris, Ketty ; Brandling-Bennett, Heather A ; Drucker, Aaron M ; Spuls, Phyllis I ; MTX Consensus for AD Survey Study Group ; the MTX Consensus for AD Survey Study Group</creatorcontrib><description>Despite the widespread off-label use of methotrexate (MTX) for the treatment of atopic dermatitis (AD), there is limited high-quality evidence on dosing regimens and existing guidelines do not provide clear recommendations regarding dosing strategies. The aim of this study was to achieve international consensus among AD experts to standardize the dosing regimen for MTX treatment in adults and children with AD. An electronic Delphi (eDelphi) study was conducted from October 2021 to September 2022. Recruitment was conducted through dermatology societies and AD interest groups. Participation was open to dermatologists and dermatology residents experienced in treating AD patients with MTX. The study consisted of three online rounds. The first round was informed by a systematic review of relevant literature, and subsequent rounds were adjusted based on the results of the previous round. Participants voted on 19 proposals using a 9-point scale (1-3 disagree, 4-6 neither agree nor disagree, 7-9 agree). Consensus was achieved when at least 70% of participants agreed, and less than 15% disagreed. Proposals that did not reach consensus in the first three rounds were discussed in a consensus meeting, where consensus was defined as less than 30% disagreement. In total, 152 participants completed Round 1, 104 (68%) completed all survey rounds, and 43 (28%) joined the consensus meeting. Consensus was achieved on 7 proposals in Round 1, 4 in Round 2 and 6 in Round 3. The final 2 proposals reached consensus during the consensus meeting. Consensus topics include test dose, start dose, maximum dose, administration route, dosing schedule, management of stopping treatment, treatment duration and folic acid supplementation. This eDelphi study achieved consensus on 19 proposals related to MTX dosing for adults and children with AD. These results aim to guide prescribing decisions and encourage a standardized global approach to MTX use in AD.</description><identifier>ISSN: 0926-9959</identifier><identifier>ISSN: 1468-3083</identifier><identifier>EISSN: 1468-3083</identifier><identifier>DOI: 10.1111/jdv.20271</identifier><identifier>PMID: 39087636</identifier><language>eng</language><publisher>England</publisher><ispartof>Journal of the European Academy of Dermatology and Venereology, 2024-08</ispartof><rights>2024 The Author(s). Journal of the European Academy of Dermatology and Venereology published by John Wiley &amp; Sons Ltd on behalf of European Academy of Dermatology and Venereology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c210t-cfbd5e078a314eb9c2f96cf161ed446d1924565b3f9859b34ebd56e80da8ab233</cites><orcidid>0000-0003-1957-6600 ; 0000-0002-6664-2490 ; 0000-0002-5244-5058 ; 0000-0002-9048-2044 ; 0000-0003-4884-6286 ; 0000-0002-7388-9475 ; 0000-0002-6209-4554 ; 0000-0001-6485-3158 ; 0000-0002-6035-2863 ; 0000-0002-5793-2664</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39087636$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Caron, Anouk G M</creatorcontrib><creatorcontrib>van Huizen, Astrid M</creatorcontrib><creatorcontrib>Musters, Annelie A H</creatorcontrib><creatorcontrib>Gerbens, Louise A A</creatorcontrib><creatorcontrib>Middelkamp Hup, Maritza A</creatorcontrib><creatorcontrib>Flohr, Carsten</creatorcontrib><creatorcontrib>Irvine, Alan D</creatorcontrib><creatorcontrib>Vestergaard, Christian</creatorcontrib><creatorcontrib>Peris, Ketty</creatorcontrib><creatorcontrib>Brandling-Bennett, Heather A</creatorcontrib><creatorcontrib>Drucker, Aaron M</creatorcontrib><creatorcontrib>Spuls, Phyllis I</creatorcontrib><creatorcontrib>MTX Consensus for AD Survey Study Group</creatorcontrib><creatorcontrib>the MTX Consensus for AD Survey Study Group</creatorcontrib><title>International consensus on methotrexate dosing for patients with atopic dermatitis: An eDelphi study</title><title>Journal of the European Academy of Dermatology and Venereology</title><addtitle>J Eur Acad Dermatol Venereol</addtitle><description>Despite the widespread off-label use of methotrexate (MTX) for the treatment of atopic dermatitis (AD), there is limited high-quality evidence on dosing regimens and existing guidelines do not provide clear recommendations regarding dosing strategies. The aim of this study was to achieve international consensus among AD experts to standardize the dosing regimen for MTX treatment in adults and children with AD. An electronic Delphi (eDelphi) study was conducted from October 2021 to September 2022. Recruitment was conducted through dermatology societies and AD interest groups. Participation was open to dermatologists and dermatology residents experienced in treating AD patients with MTX. The study consisted of three online rounds. The first round was informed by a systematic review of relevant literature, and subsequent rounds were adjusted based on the results of the previous round. Participants voted on 19 proposals using a 9-point scale (1-3 disagree, 4-6 neither agree nor disagree, 7-9 agree). Consensus was achieved when at least 70% of participants agreed, and less than 15% disagreed. Proposals that did not reach consensus in the first three rounds were discussed in a consensus meeting, where consensus was defined as less than 30% disagreement. In total, 152 participants completed Round 1, 104 (68%) completed all survey rounds, and 43 (28%) joined the consensus meeting. Consensus was achieved on 7 proposals in Round 1, 4 in Round 2 and 6 in Round 3. The final 2 proposals reached consensus during the consensus meeting. Consensus topics include test dose, start dose, maximum dose, administration route, dosing schedule, management of stopping treatment, treatment duration and folic acid supplementation. This eDelphi study achieved consensus on 19 proposals related to MTX dosing for adults and children with AD. These results aim to guide prescribing decisions and encourage a standardized global approach to MTX use in AD.</description><issn>0926-9959</issn><issn>1468-3083</issn><issn>1468-3083</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo90D1PwzAQgGELgWgpDPwB5BGGFDtOnJitKl-VKrHAHDn2hbpK7GA7QP89AQq3nHR6dMOL0DklczrO9Va_z1OSFvQATWnGy4SRkh2iKREpT4TIxQSdhLAlhFCal8dowgQpC874FOmVjeCtjMZZ2WLlbAAbhoCdxR3EjYsePmUErF0w9hU3zuN-1GBjwB8mbrCMrjcKa_DdeI8m3OCFxXALbb8xOMRB707RUSPbAGf7PUMv93fPy8dk_fSwWi7WiUopiYlqap0DKUrJaAa1UGkjuGoop6CzjGsq0iznec0aUeaiZqPROYeSaFnKOmVshi5___bevQ0QYtWZoKBtpQU3hGrMwkXORUFGevVLlXcheGiq3ptO-l1FSfUdtRqjVj9RR3uxfzvUHeh_-VeRfQGroHQ_</recordid><startdate>20240801</startdate><enddate>20240801</enddate><creator>Caron, Anouk G M</creator><creator>van Huizen, Astrid M</creator><creator>Musters, Annelie A H</creator><creator>Gerbens, Louise A A</creator><creator>Middelkamp Hup, Maritza A</creator><creator>Flohr, Carsten</creator><creator>Irvine, Alan D</creator><creator>Vestergaard, Christian</creator><creator>Peris, Ketty</creator><creator>Brandling-Bennett, Heather A</creator><creator>Drucker, Aaron M</creator><creator>Spuls, Phyllis I</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1957-6600</orcidid><orcidid>https://orcid.org/0000-0002-6664-2490</orcidid><orcidid>https://orcid.org/0000-0002-5244-5058</orcidid><orcidid>https://orcid.org/0000-0002-9048-2044</orcidid><orcidid>https://orcid.org/0000-0003-4884-6286</orcidid><orcidid>https://orcid.org/0000-0002-7388-9475</orcidid><orcidid>https://orcid.org/0000-0002-6209-4554</orcidid><orcidid>https://orcid.org/0000-0001-6485-3158</orcidid><orcidid>https://orcid.org/0000-0002-6035-2863</orcidid><orcidid>https://orcid.org/0000-0002-5793-2664</orcidid></search><sort><creationdate>20240801</creationdate><title>International consensus on methotrexate dosing for patients with atopic dermatitis: An eDelphi study</title><author>Caron, Anouk G M ; van Huizen, Astrid M ; Musters, Annelie A H ; Gerbens, Louise A A ; Middelkamp Hup, Maritza A ; Flohr, Carsten ; Irvine, Alan D ; Vestergaard, Christian ; Peris, Ketty ; Brandling-Bennett, Heather A ; Drucker, Aaron M ; Spuls, Phyllis I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c210t-cfbd5e078a314eb9c2f96cf161ed446d1924565b3f9859b34ebd56e80da8ab233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Caron, Anouk G M</creatorcontrib><creatorcontrib>van Huizen, Astrid M</creatorcontrib><creatorcontrib>Musters, Annelie A H</creatorcontrib><creatorcontrib>Gerbens, Louise A A</creatorcontrib><creatorcontrib>Middelkamp Hup, Maritza A</creatorcontrib><creatorcontrib>Flohr, Carsten</creatorcontrib><creatorcontrib>Irvine, Alan D</creatorcontrib><creatorcontrib>Vestergaard, Christian</creatorcontrib><creatorcontrib>Peris, Ketty</creatorcontrib><creatorcontrib>Brandling-Bennett, Heather A</creatorcontrib><creatorcontrib>Drucker, Aaron M</creatorcontrib><creatorcontrib>Spuls, Phyllis I</creatorcontrib><creatorcontrib>MTX Consensus for AD Survey Study Group</creatorcontrib><creatorcontrib>the MTX Consensus for AD Survey Study Group</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the European Academy of Dermatology and Venereology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Caron, Anouk G M</au><au>van Huizen, Astrid M</au><au>Musters, Annelie A H</au><au>Gerbens, Louise A A</au><au>Middelkamp Hup, Maritza A</au><au>Flohr, Carsten</au><au>Irvine, Alan D</au><au>Vestergaard, Christian</au><au>Peris, Ketty</au><au>Brandling-Bennett, Heather A</au><au>Drucker, Aaron M</au><au>Spuls, Phyllis I</au><aucorp>MTX Consensus for AD Survey Study Group</aucorp><aucorp>the MTX Consensus for AD Survey Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>International consensus on methotrexate dosing for patients with atopic dermatitis: An eDelphi study</atitle><jtitle>Journal of the European Academy of Dermatology and Venereology</jtitle><addtitle>J Eur Acad Dermatol Venereol</addtitle><date>2024-08-01</date><risdate>2024</risdate><issn>0926-9959</issn><issn>1468-3083</issn><eissn>1468-3083</eissn><abstract>Despite the widespread off-label use of methotrexate (MTX) for the treatment of atopic dermatitis (AD), there is limited high-quality evidence on dosing regimens and existing guidelines do not provide clear recommendations regarding dosing strategies. The aim of this study was to achieve international consensus among AD experts to standardize the dosing regimen for MTX treatment in adults and children with AD. An electronic Delphi (eDelphi) study was conducted from October 2021 to September 2022. Recruitment was conducted through dermatology societies and AD interest groups. Participation was open to dermatologists and dermatology residents experienced in treating AD patients with MTX. The study consisted of three online rounds. The first round was informed by a systematic review of relevant literature, and subsequent rounds were adjusted based on the results of the previous round. Participants voted on 19 proposals using a 9-point scale (1-3 disagree, 4-6 neither agree nor disagree, 7-9 agree). Consensus was achieved when at least 70% of participants agreed, and less than 15% disagreed. Proposals that did not reach consensus in the first three rounds were discussed in a consensus meeting, where consensus was defined as less than 30% disagreement. In total, 152 participants completed Round 1, 104 (68%) completed all survey rounds, and 43 (28%) joined the consensus meeting. Consensus was achieved on 7 proposals in Round 1, 4 in Round 2 and 6 in Round 3. The final 2 proposals reached consensus during the consensus meeting. Consensus topics include test dose, start dose, maximum dose, administration route, dosing schedule, management of stopping treatment, treatment duration and folic acid supplementation. This eDelphi study achieved consensus on 19 proposals related to MTX dosing for adults and children with AD. These results aim to guide prescribing decisions and encourage a standardized global approach to MTX use in AD.</abstract><cop>England</cop><pmid>39087636</pmid><doi>10.1111/jdv.20271</doi><orcidid>https://orcid.org/0000-0003-1957-6600</orcidid><orcidid>https://orcid.org/0000-0002-6664-2490</orcidid><orcidid>https://orcid.org/0000-0002-5244-5058</orcidid><orcidid>https://orcid.org/0000-0002-9048-2044</orcidid><orcidid>https://orcid.org/0000-0003-4884-6286</orcidid><orcidid>https://orcid.org/0000-0002-7388-9475</orcidid><orcidid>https://orcid.org/0000-0002-6209-4554</orcidid><orcidid>https://orcid.org/0000-0001-6485-3158</orcidid><orcidid>https://orcid.org/0000-0002-6035-2863</orcidid><orcidid>https://orcid.org/0000-0002-5793-2664</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0926-9959
ispartof Journal of the European Academy of Dermatology and Venereology, 2024-08
issn 0926-9959
1468-3083
1468-3083
language eng
recordid cdi_proquest_miscellaneous_3086956970
source Wiley Online Library Journals Frontfile Complete
title International consensus on methotrexate dosing for patients with atopic dermatitis: An eDelphi study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T17%3A27%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=International%20consensus%20on%20methotrexate%20dosing%20for%20patients%20with%20atopic%20dermatitis:%20An%20eDelphi%20study&rft.jtitle=Journal%20of%20the%20European%20Academy%20of%20Dermatology%20and%20Venereology&rft.au=Caron,%20Anouk%20G%20M&rft.aucorp=MTX%20Consensus%20for%20AD%20Survey%20Study%20Group&rft.date=2024-08-01&rft.issn=0926-9959&rft.eissn=1468-3083&rft_id=info:doi/10.1111/jdv.20271&rft_dat=%3Cproquest_cross%3E3086956970%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3086956970&rft_id=info:pmid/39087636&rfr_iscdi=true